Key clinical point: Treatment of patients with atopic dermatitis (AD) with dupilumab is not associated with the development of primary or recurrent malignancy.
Major finding: Dupilumab-exposed and unexposed patients had comparable incidence rates of primary malignancies (adjusted hazard ratio [aHR], 1.010; P = .946), keratinocyte cancers (aHR, 0.994; P = .973), and recurrent cancers (aHR, 0.828; P = .758) per 1,000 person-years.
Study details: This single-center 5-year retrospective study included 9,707 patients with AD, of which 1,627 patients received dupilumab treatment.
Disclosures: This study did not receive any funding. Some authors declared serving as consultants for and/or receiving research funds from various organizations.
Source: Owji S et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2022 (Dec 26). Doi: 10.1016/j.jaip.2022.12.018.